drugset / Trial / NCT00801125
Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to demonstrate the safety, tolerability and clinical benefit of TYSABRI® (natalizumab) in patients with moderately to severely active Crohn's disease.
Timeline
- Start
- 2008-12
- Primary completion
- 2010-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | natalizumab | Monoclonal antibody | — | — |